FDA Grants Fast Track Designation to ContraFect's CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA August 17, 2015
ContraFect Corporation Announces Issuance of Key Patent Covering Novel Lysin Technology July 17, 2015
ContraFect Corporation Adds Former Cubist Executive Steven C. Gilman, PhD, to Board of Directors as Executive Chairman May 20, 2015
ContraFect Corporation Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA April 29, 2015
